Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
-
JA Solar Deep Blue 3.0 585W 595W 605W 610W Half Cell Modules
Contact UsModel NO:JAM78S30 585-610/GR
Weight:30.5 kg
Transport Package:Wooden Pallet and Carton Packing
Specification:2456±2mm*1134±2mm*35±1mm
Trademark:JA solar
Origin:China -
PGA temporary plugging agent
Contact UsPGA fully degradable temporary plugging agent is temporary plugging agent developed mainly with degradable materials to meet the needs of oil fields under various temperatures and working conditions.
-
Gel & Clot Activator Tube
Contact UsGel and clot activator tube is used for blood serum biochemistry, immunology and drug testing, etc.
Reviews
There are no reviews yet.